Prospects for prevention of Salmonella infection in children through vaccination

Current Opinion in Infectious Diseases

Volumn 26, Issue 3, 2013, Pages 254-262

  McGregor, Alastair C ^a   Waddington, Claire S ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

children; enteric fever; salmonella; typhoid; vaccine

Indexed keywords

LIVE VACCINE; SALMONELLOSIS VACCINE;

AFRICA; CHILD; DRUG EFFICACY; HUMAN; INCIDENCE; INFECTION PREVENTION; REVIEW; SALMONELLA TYPHI; SALMONELLOSIS; VACCINATION;

CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; SALMONELLA INFECTIONS; SALMONELLA VACCINES; VACCINES, ATTENUATED; VACCINES, CONJUGATE;

EID: 84876874493     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835fb829     Document Type: Review

References (132)

1. Miller SI, Pegues DA. Salmonella species, including Salmonella Typhi. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingston; 2000. pp. 2344-2347.
2. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-353.
3. Ochiai RL, Wang X, von Seidlein L, et al. Salmonella Paratyphi A rates, Asia. Emerg Infect Dis 2005; 11:1764-1766.
4. Woods CW, Murdoch DR, Zimmerman MD, et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006; 100:1063-1067.
5. Health Protection Agency. Enteric fever. 2012 http://www.hpa.org.uk/ Topics/InfectiousDiseases/InfectionsAZ/TravelHealth/EpidemiologicalData/ GastrointestinalInfections/travEntericfever/. [Accessed 14 August 2012]
6. Boggild AK, Castelli F, Gautret P, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 2010; 28:7389-7395.
7. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008; 86:260-268.
8. Brooks WA, Hossain A, Goswami D, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005; 11:326- 329.
9. Saha SK, Baqui AH, Hanif M, et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001; 20:521-524.
10. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-737.
11. Clemens JD. Meeting on establishment of consortium to study invasive salmonelloses in Sub-Saharan Africa. Emerg Infect Dis 2009; 15:e2.
12. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:417-432.
13. Nielsen MV, Sarpong N, Krumkamp R, et al. Incidence and characteristics of bacteremia among children in rural Ghana. PLoS One 2012; 7:e44063.
14. Tabu C, Breiman RF, Ochieng B, et al. Differing burden and epidemiology of non-Typhi Salmonella bacteremia in rural and urban Kenya, 2006-2009. PLoS One 2012; 7:e31237.
15. Thriemer K, Ley B, Ame S, et al. The burden of invasive bacterial infections in Pemba, Zanzibar. PLoS One 2012; 7:e30350.
16. Obaro S, Lawson L, Essen U, et al. Community acquired bacteremia in young children from central Nigeria: a pilot study. BMC Infect Dis 2011; 11:137.
17. Marks F, Adu-Sarkodie Y, Hunger F, et al. Typhoid fever among children, Ghana. Emerg Infect Dis 2010; 16:1796-1797.
18. Muyembe-Tamfum JJ, Veyi J, Kaswa M, et al. An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo. Travel Med Infect Dis 2009; 7:40-43.
19. Mweu E, English M. Typhoid fever in children in Africa. Trop Med Int Health 2008; 13:532-540.
20. Lutterloh E, Likaka L, Sejvar J, et al. Multidrug-resistant typhoid fever with neurologic findings on the Malawi-Mozambique border. Clin Infect Dis 2012; 54:1100-1106.
21. Neil KP, Sodha SV, Lukwago L, et al. A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008-2009. Clin Infect Dis 2012; 54:1091-1099.
22. Breiman RF, Cosmas L, Njuguna H, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. PLoS One 2012; 7:e29119.
23. Khan MI, Ochiai RL, von Seidlein L, et al. Nontyphoidal Salmonella rates in febrile children at sites in five Asian countries. Trop Med Int Health 2010; 15:960-963.
24. Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195:895-904.
25. Morpeth SC, Ramadhani HO, Crump JA. Invasive non-Typhi Salmonella disease in Africa. Clin Infect Dis 2009; 49:606-611.
26. Mabey DC, Brown A, Greenwood BM. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis 1987; 155:1319- 1321.
27. Brent AJ, Oundo JO, Mwangi I, et al. Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J 2006; 25:230-236.
28. Graham SM, Walsh AL, Molyneux EM, et al. Clinical presentation of nontyphoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med Hyg 2000; 94:310-314.
29. Sigauque B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J 2009; 28:108-113.
30. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005; 352:39-47.
31. Mackenzie G, Ceesay SJ, Hill PC, et al. A decline in the incidence of invasive nontyphoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One 2010; 5:e10568.
32. Mtove G, Amos B, Nadjm B, et al. Decreasing incidence of severe malaria and community acquired bacteraemia among hospitalized children in Muheza, North-Eastern Tanzania, 2006-2010. Malar J 2011; 10:320.
33. Scott JA, Berkley JA, Mwangi I, et al. Relation between Falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316-1323.
34. Tulchinsky TH, Burla E, Clayman M, et al. Safety of community drinking-water and outbreaks of waterborne enteric disease: Israel, 1976-97. Bull World Health Organ 2000; 78:1466-1473.
35. Sur D, Ali M, von Seidlein L, et al. Comparisons of predictors for typhoid and paratyphoid fever in Kolkata, India. BMC Public Health 2007; 7:289.
36. Swaddiwudhipong W, Kanlayanaphotporn J. A common-source water-borne outbreak of multidrug-resistant typhoid fever in a rural Thai community. J Med Assoc Thai 2001; 84:1513-1517.
37. Baker S, Holt KE, Clements AC, et al. Combined high-resolution genotyping and geospatial analysis reveals modes of endemic urban typhoid fever transmission. Open Biol 2011; 1:110008.
38. Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar Enteritidis and S. enterica serovar Typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963-969.
39. Milledge J, Calis JC, Graham SM, et al. Aetiology of neonatal sepsis in Blantyre, Malawi: 1996-2001. Ann Trop Paediatr 2005; 25:101-110.
40. Kariuki S, Revathi G, Kariuki N, et al. Invasive multidrug-resistant nontyphoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585-591.
41. Nkuo-Akenji TK, Ntemgwa ML, Ndip RN. Asymptomatic salmonellosis and drug susceptibility in the Buea District, Cameroon. Cent Afr J Med 2001; 47:254-257.
42. Dione MM, Ikumapayi UN, Saha D, et al. Clonal differences between nontyphoidal Salmonella (NTS) recovered from children and animals living in close contact in the Gambia. PLoS Negl Trop Dis 2011; 5:e1148.
43. Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413-422.
44. Feasey NA, Dougan G, Kingsley RA, et al. Invasive nontyphoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet 2012; 379:2489-2499.
45. Nelson CB, de Quadros C. Coalition against Typhoid (CaT): a new, global initiative to advance typhoid vaccination. Vaccine 2011; 29:6443.
46. Engels EA, Falagas ME, Lau J, et al. Typhoid fever vaccines: a metaanalysis of studies on efficacy and toxicity. Br Med J 1998; 316:110- 116.
47. Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a Salmonella Typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990; 8:81-84.
48. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1:1049-1052.
49. Levine MM, Ferreccio C, Abrego P, et al. Duration of efficacy of Ty21a, attenuated Salmonella Typhi live oral vaccine. Vaccine 1999; 17 (Suppl 2): S22-S27.
50. Wahdan MH, Serie C, Cerisier Y, et al. A controlled field trial of live Salmonella Typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982; 145:292-295.
51. Klugman KP, Gilbertson IT, Koornhoff HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2: 1165-1169.
52. Khan MI, Soofi SB, Ochiai RL, et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012; 30:5389-5395.
53. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-344.
54. Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001; 79:625-631.
55. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-1269.
56. Fraser A, Paul M, Goldberg E, et al. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007; 25:7848-7857.
57. Cryz SJ Jr, Vanprapar N, Thisyakorn U, et al. Safety and immunogenicity of Salmonella Typhi Ty21a vaccine in young Thai children. Infect Immun 1993; 61:1149-1151.
58. Murphy JR, Grez L, Schlesinger L, et al. Immunogenicity of Salmonella Typhi Ty21a vaccine for young children. Infect Immun 1991; 59:4291-4293.
59. Ohtake S, Martin R, Saxena A, et al. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011; 29:2761-2771.
60. Levine MM, Ferreccio C, Black RE, et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007; 45 (Suppl 1):S24-S28.
61. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011; 10:307-322.
62. Overbosch D, Peyron F, Picot N, et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J Travel Med 2005; 12:319-326.
63. Lebacq E. Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration. BioDrugs 2001; 15 (Suppl 1):5-12.
64. Martin LB. Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis 2012; 25:489-499.
65. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-220.
66. Makela PH, Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines 2002; 1:399-410.
67. Mathew JL. Conjugate typhoid vaccine(s) in the Indian context. Indian Pediatr 2009; 46:182-184.
68. Shah NK. Indian conjugate Vi typhoid vaccine: do we have enough evidence? Indian Pediatr 2009; 46:181-182.
69. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390- 1391.
70. Thiem VD, Lin FY, Canh do G, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011; 18:730-735.
71. Bio-Med. Vi conjugate typhoid Vaccine - Peda Typh. http://www.biomed.- co.in/typh-vaccine.html. [Accessed 10 September 2012]
72. Clinical Trials Registry - India. A study to evaluate the immunogenicity and safety of BBIL's typhoid Vi capsular polysaccharide-tetanus toxoid protein conjugate vaccine vs. reference vaccine in healthy subjects. http://www.ctri. nic.in/Clinicaltrials/pmaindet2.php?trialid3241. [Accessed 10 September 2012].
73. Szu SC, Taylor DN, Trofa AC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994; 62:4440-4444.
74. Micoli F, Rondini S, Pisoni I, et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011; 29:712-720.
75. Vi-based Vaccines for Asia Initiative. Vi Conjugate Vaccine Program. 2010. http://www.viva.ivi.int/ViConjugateVaccineProgram/VCVP.html. [Accessed 20 August 2012]
76. Haque S, Jailkhani B, Sengupta S, et al., Design of T cell epitope rich OmpC peptide and its conjugation with Vi-polysaccharide: a candidate vaccine for typhoid fever. J Immunol 2011. 186(Meeting Abstract Supplement): 106.26.
77. Ali A, An SJ, Cui C, et al. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid. Hum Vaccin Immunother 2012; 8:189-193.
78. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella Typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975; 131:553-558.
79. Kopecko DJ, Sieber H, Ures JA, et al. Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years. Int J Med Microbiol 2009; 299:233- 246.
80. Tran TH, Nguyen TD, Nguyen TT, et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 2010; 5: e11778.
81. Lyon CE, Sadigh KS, Carmolli MP, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine 2010; 28:3602-3608.
82. Kirkpatrick BD, McKenzie R, O'Neill JP, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24:116-123.
83. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007; 45 (Suppl 1):S20-S23.
84. Wang JY, Noriega FR, Galen JE, et al. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 2000; 68:4647-4652.
85. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338:1055- 1059.
86. Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 2005; 12:275-281.
87. Wahid R, Simon R, Zafar SJ, et al. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012; 19:825-834.
88. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 2010; 30:6047- 6053.
89. ClinicalTrials.gov. Phase I Safety and Efficacy Study of CVD 1902, a live, attenuated oral vaccine to prevent Salmonella enterica serovar Paratyphi A Infection. 2010. http://www.clinicaltrials.gov/ct2/show/NCT01129453. [Accessed 17 August 2012]
90. Roland KL, Tinge SA, Kochi SK, et al. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine 2010; 28:3679-3687.
91. Gat O, Galen JE, Tennant S, et al. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis 2011; 5:e1373.
92. Konadu EY, Lin FY, Ho VA, et al. Phase 1 and phase 2 studies of Salmonella enterica serovar Paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 2000; 68:1529-1534.
93. Martin LB, Micoli F, Rondini S, et al. Development of a conjugate vaccine for enteric fever. In: 6th International Conference on Vaccines for Enteric Diseases. 2011; Cannes, France.
94. Simon R, Tennant SM, Wang JY, et al. Salmonella enterica serovar Enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun 2011; 79:4240-4249.
95. Allam US, Krishna MG, Lahiri A, et al. Salmonella enterica serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid. PLoS One 2011; 6:e16667.
96. Pesciaroli M, Aloisio F, Ammendola S, et al. An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection. Vaccine 2011; 29:1783-1790.
97. Tennant SM, Wang JY, Galen JE, et al. Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 2011; 79:4175-4185.
98. Choi J, Shin D, Ryu S. Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice. Vaccine 2010; 28:6436-6444.
99. Gil-Cruz C, Bobat S, Marshall JL, et al. The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response. Proc Natl Acad Sci U S A 2009; 106:9803-9808.
100. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother 2012; 8:494-498.
101. MacLennan CA, Gilchrist JJ, Gordon MA, et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 2010; 328:508-512.
102. GordonMA. Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis. Curr Opin Infect Dis 2011; 24:484-489.
103. WHO. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007-conclusions and recommendations. Wkly Epidemiol Rec 2008; 83:1-15.
104. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49- 59
105. Whitaker JA, Franco-Paredes C, del Rio C, et al. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009; 16:46-52.
106. Ochiai RL, Acosta CJ, Agtini M, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis 2007; 45 (Suppl 1):S34-S38.
107. Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010; 9:485-496.
108. Sanofi-Pasteur. Sanofi Pasteur's Typhoid Vaccine, Typhim Vi1, Granted Prequalification by the World Health Organization. 2011 June 23, 2011. http://www.sanofipasteur.com/sanofi-pasteur4/articles/259-sanofi-pasteurs- typhoid-vaccine-typhim-viu-granted-prequalification-by-the-world- healthorganization. html. [Accessed 14 August 2012].
109. DeRoeck D, Ochiai RL, Yang J, et al. Typhoid vaccination: the Asian experience. Expert Rev Vaccines 2008; 7:547-560.
110. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 1995; 155:2293-2299.
111. Keitel WA, Bond NL, Zahradnik JM, et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12:195-199.
112. LevineMM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis 1982; 146:724-726.
113. Ames WR, Robins M. Age and sex as factors in the development of the typhoid carrier state, and a method for estimating carrier prevalence. Am J Public Health Nations Health 1943; 33:221-230.
114. Lai CW, Chan RC, Cheng AF, et al. Common bile duct stones: a cause of chronic salmonellosis. Am J Gastroenterol 1992; 87:1198-1199.
115. Dong BQ, Yang J, Wang XY, et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. Bull World Health Organ 2010; 88:689-696.
116. Yang HH, Dong BQ, Lin M, et al., Experience of school-based vaccination in a typhoid fever endemic area using Vi manufactured in China. In: Typhoid fever a neglected disease: Towards vaccine introduction policy. Annecy, France. 2007.
117. Podda A, Saul AJ, Arora R, et al. Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009. J Infect Dev Ctries 2010; 4:404-411.
118. WHO, Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, November 2010: summary, conclusions and recommendations. Wkly Epidemiol Rec 2011. 86: 1-16.
119. World Health Organisation. Recommended routine immunization for children. 2012 http://www.who.int/immunization/policy/Immunization-rou tine-table2.pdf. [Accessed 5 September 2012]
120. Khan MI, Ochiai RL, Hamza HB, et al., Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials 2006; 7:17.
121. Agtini MD, Ochiai RL, Soeharno R, et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 2006; 120:1081-1087.
122. Thiem VD, Danovaro-Holliday MC, Canh do G, et al. The feasibility of a school-based VI polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy. Southeast Asian J Trop Med Public Health 2006; 37:515- 522.
123. Farooqui A, Khan A, Kazmi SU. Investigation of a community outbreak of typhoid fever associated with drinking water. BMC Public Health 2009; 9:476.
124. Kelly-Hope LA, Alonso WJ, Thiem VD, et al. Geographical distribution and risk factors associated with enteric diseases in Vietnam. Am J Trop Med Hyg 2007; 76:706-712.
125. Lin FY, Vo AH, Phan VB, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000; 62:644-648.
126. Merselis JG Jr, Kaye D, Connolly CS, et al. Quantitative bacteriology of the typhoid carrier state. Am J Trop Med Hyg 1964; 13:425-429.
127. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-1973.
128. Coalition Against Typhoid. http://www.sabin.org/programs/vaccine- advocacy/ coalition-against-typhoid. [Accessed 5 November 2012]
129. Maurice J. A first step in bringing typhoid fever out of the closet. Lancet 2012; 379:699-700.
130. Poulos C, Riewpaiboon A, Stewart JF, et al. Cost of illness due to typhoid fever in five Asian countries. Trop Med Int Health 2011; 16:314-323.
131. Bahl R, Sinha A, Poulos C, et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr 2004; 22:304-310.
132. Sanchez-Vargas FM, Abu-El-Haija MA, Gomez-Duarte OG. Salmonella infections: an update on epidemiology, management, and prevention. Travel Med Infect Dis 2011; 9:263-277.